Sarepta: Sarepta and Roche aim to resume paused Elevidys trials following patient death
Sarepta and Roche announced a 16-year-old US patient dosed with Elevidys died of acute liver failure in March 2025. The post Sarepta and Roche aim to resume paused Elevidys trials following patient death appeared first on Clinical Trials Arena.
Read full article »
Sarepta is a Massachusetts-based biotechnology company that discovers and develops genetic medicines for the treatment of neuromuscular diseases.
Read more